Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Wirden

Showing results (1-10 of 98) with videos related to

Pageof 10
Sort By:
Journal of the International AIDS Society|November 15, 2014
Less frequent follow-up in routine care than in trials does not impact resistance selection in patients failing DRV/r or ATV/r first line treatmentAnne-Genevieve Marcelin, Charlotte Charpentier, Marc Wirden, et al.
Antiviral Therapy|February 22, 2007
Impact of HIV-1 reverse transcriptase polymorphism at codons 211 and 228 on virological response to didanosineAnne-Genevieve Marcelin, Philippe Flandre, Andre Furco, et al.
Journal of Medical Virology|November 25, 2003
Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failureAnne-Geneviève Marcelin, Constance Delaugerre, Marc Wirden, et al.
Journal of Medical Virology|January 25, 2007
Relationship between mutations in HIV-1 RNase H domain and nucleoside reverse transcriptase inhibitors resistance mutations in naïve and pre-treated HIV infected patientsBénédicte Roquebert, Marc Wirden, Anne Simon, et al.
AIDS (London, England)|April 7, 2007
Primary genotypic resistance of HIV-1 to the maturation inhibitor PA-457 in protease inhibitor-experienced patientsIsabelle Malet, Marc Wirden, Anne Derache, et al.
AIDS (London, England)|October 26, 2013
Characterization of CRF56_cpx, a new circulating B/CRF02/G recombinant form identified in MSM in FranceMarie Leoz, Felix Feyertag, Charlotte Charpentier, et al.
The Journal of Antimicrobial Chemotherapy|October 22, 2024
Emergent resistance-associated mutations at first- or second-line HIV-1 virologic failure with second-generation InSTIs in two- and three-drug regimens: the Virostar-1 studyAnne-Geneviève Marcelin, Cathia Soulie, Marc Wirden, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|July 14, 2010
Role of HIV-1 DNA levels as clinical marker of HIV-1-associated nephropathiesHassane Izzedine, Veena Acharya, Marc Wirden, et al.
Antimicrobial Agents and Chemotherapy|February 4, 2010
International cohort analysis of the antiviral activities of zidovudine and tenofovir in the presence of the K65R mutation in reverse transcriptasePhilip M Grant, Jonathan Taylor, Andrew B Nevins, et al.
The Journal of Antimicrobial Chemotherapy|February 18, 2020
M184V/I does not impact the efficacy of abacavir/lamivudine/dolutegravir use as switch therapy in virologically suppressed patientsAude Jary, Anne-Geneviève Marcelin, Charlotte Charpentier, et al.
Pageof 10

Showing results (1-10 of 98) with videos related to

Sort By:
Pageof 10
Journal of the International AIDS Society|November 15, 2014
Less frequent follow-up in routine care than in trials does not impact resistance selection in patients failing DRV/r or ATV/r first line treatmentAnne-Genevieve Marcelin, Charlotte Charpentier, Marc Wirden, et al.
Antiviral Therapy|February 22, 2007
Impact of HIV-1 reverse transcriptase polymorphism at codons 211 and 228 on virological response to didanosineAnne-Genevieve Marcelin, Philippe Flandre, Andre Furco, et al.
Journal of Medical Virology|November 25, 2003
Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failureAnne-Geneviève Marcelin, Constance Delaugerre, Marc Wirden, et al.
Journal of Medical Virology|January 25, 2007
Relationship between mutations in HIV-1 RNase H domain and nucleoside reverse transcriptase inhibitors resistance mutations in naïve and pre-treated HIV infected patientsBénédicte Roquebert, Marc Wirden, Anne Simon, et al.
AIDS (London, England)|April 7, 2007
Primary genotypic resistance of HIV-1 to the maturation inhibitor PA-457 in protease inhibitor-experienced patientsIsabelle Malet, Marc Wirden, Anne Derache, et al.
AIDS (London, England)|October 26, 2013
Characterization of CRF56_cpx, a new circulating B/CRF02/G recombinant form identified in MSM in FranceMarie Leoz, Felix Feyertag, Charlotte Charpentier, et al.
The Journal of Antimicrobial Chemotherapy|October 22, 2024
Emergent resistance-associated mutations at first- or second-line HIV-1 virologic failure with second-generation InSTIs in two- and three-drug regimens: the Virostar-1 studyAnne-Geneviève Marcelin, Cathia Soulie, Marc Wirden, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|July 14, 2010
Role of HIV-1 DNA levels as clinical marker of HIV-1-associated nephropathiesHassane Izzedine, Veena Acharya, Marc Wirden, et al.
Antimicrobial Agents and Chemotherapy|February 4, 2010
International cohort analysis of the antiviral activities of zidovudine and tenofovir in the presence of the K65R mutation in reverse transcriptasePhilip M Grant, Jonathan Taylor, Andrew B Nevins, et al.
The Journal of Antimicrobial Chemotherapy|February 18, 2020
M184V/I does not impact the efficacy of abacavir/lamivudine/dolutegravir use as switch therapy in virologically suppressed patientsAude Jary, Anne-Geneviève Marcelin, Charlotte Charpentier, et al.
Pageof 10